- New alliance will crack down on adulterated products touting dietary supplement claims
- Adherence among chronic disease patients can lead to big savings
- FDA looks to simplify drug info packets
- FDA approves new schizophrenia drug
- As innovaters prep for patent cliff, generics prosper from patent losses
PRINCETON, N.J. — The Food and Drug Administration has approved a psychiatric drug for treating bipolar disorder when used in combination with one of two other drugs.
The FDA approved Abilify (aripiprazole), made by Bristol-Myers Squibb and Otsuka Pharmaceutical, as an adjunct to lithium or valproate for maintenance treatment of bipolar I disorder.
The FDA approved Abilify as an adjunct to lithium or valproate for acute treatment of manic or mixed episodes associated with bipolar I disorder in May 2008. The drug also is approved as a stand-alone treatment for the disorder.